Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Beelen, Dietrich Wilhelm, Trenschel, Rudolf, Stelljes, Matthias, Groth, Christoph, Masszi, Tamas, Remenyi, Peter, Wagner-Drouet, Eva-Maria, Hauptrock, Beate, Dreger, Peter, Luft, Thomas, Bethge, Wolfgang, Vogel, Wichard, Ciceri, Fabio, Peccatori, Jacopo, Stoelzel, Friedrich, Schetelig, Johannes, Junghanss, Christian, Grosse-Thie, Christina, Michallet, Mauricette, Labussiere-Wallet, Helene, Schaefer-Eckart, Kerstin, Dressler, Sabine, Grigoleit, Goetz Ulrich, Mielke, Stephan ORCID: 0000-0002-8325-9215, Scheid, Christof, Holtick, Udo, Patriarca, Francesca, Medeot, Marta, Rambaldi, Alessandro, Mico, Maria Caterina, Niederwieser, Dietger, Franke, Georg-Nikolaus, Hilgendorf, Inken ORCID: 0000-0003-2038-9730, Winkelmann, Nils Rudolf, Russo, Domenico, Socie, Gerard, de Latour, Regis Peffault, Holler, Ernst, Wolff, Daniel, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Menzel, Helge, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, Grass, Sandra, Iori, Anna Paola, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Hemmelmann, Claudia, Tribanek, Michael, Klein, Anja, Mylius, Heidrun Anke, Baumgart, Joachim, Dzierzak-Mietla, Monika and Markiewicz, Miroslaw (2020). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol., 7 (1). S. E28 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Schroeder, Thomas Michael, Rautenberg, Christina, Christopeit, Max, Stelljes, Matthias, Schmidt, Eva, Groth, Christoph, Scheid, Christoph, Holtick, Udo, Klein, Stefan A., Beelen, Dietrich W., Nachtkamp, Kathrin, Haas, Rainer, Germing, Ulrich, Kroeger, Nicolaus and Kobbe, Guido (2018). Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Mar 29 17:00:10 2024 CET.